Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Genelux Corporation, a late clinical-stage immuno-oncology company, has recently published positive Phase I trial results for their drug Olvi-Vec in the journal Frontiers in Immunology. The purpose of the trial was to assess the safety, feasibility, and immune activating effects of administering Olvi-Vec directly into the pleural cavity of patients with malignant pleural effusion (MPE) caused by..